The clinical and economic burden of chronic obstructive pulmonary disease in the USA

Anthony J Guarascio1
Shauntá M Ray1
Christopher K Finch2,3
Timothy H Self2
1University of Tennessee College of Pharmacy, Knoxville, 2University of Tennessee College of Pharmacy, Memphis, TN, USA; 3Methodist University Hospital, Memphis, TN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the USA. In 2010, the cost of COPD in the USA was projected to be approximately US$50 billion, which includes $20 billion in indirect costs and $30 billion in direct health care expenditures. These costs can be expected to continue to rise with this progressive disease. Costs increase with increasing severity of disease, and hospital stays account for the majority of these costs. Patients are diagnosed with COPD following a multifactorial assessment that includes spirometry, clinical presentation, symptomatology, and risk factors. Smoking cessation interventions are the most influential factor in COPD management. The primary goal of chronic COPD management is stabilization of chronic disease and prevention of acute exacerbations. Bronchodilators are the mainstay of COPD therapy. Patients with few symptoms and low exacerbation risk should be treated with a short-acting bronchodilator as needed for breathlessness. Progression of symptoms, as well as possible decline in forced expiratory volume in the first second of expiration (FEV1), warrant the use of long-acting bronchodilators. For patients with frequent exacerbations with or without consistent symptoms, inhaled corticosteroids should be considered in addition to a long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) and may even consist of “triple therapy” with all three agents with more severe disease. Phosphodiesterase-4 inhibitors may be an option in patients with frequent exacerbations and symptoms of chronic bronchitis. In addition to a variety of novel ultra-LABAs, LAMAs and combination bronchodilator and inhaled corticosteroid (ICS) therapies, other bronchodilators with a variety of mechanisms are also being considered, to expand therapeutic options for the treatment of COPD. With more than 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex as benefits of therapy are balanced with the limitations and needs of each patient.

Keywords: chronic obstructive pulmonary disease, COPD, clinical burden, economic burden

Introduction

Chronic obstructive pulmonary disease (COPD) is a term that encompasses both chronic bronchitis and emphysema. These two diseases are characterized by obstruction to airflow that interferes with normal breathing. Since both of these diseases often coexist, many health care professionals prefer the term COPD. Although some patients may have components of both COPD and another obstructive airway disease, asthma, this review concerns only COPD. Because of the significant worldwide burden of disease and economic implications, evidence-based guidelines, the Global initiative for chronic Obstructive Lung Disease (GOLD), were launched more than a decade ago with frequent updates.
While more than 12 million Americans are known to have COPD, up to 24 million have evidence of impaired lung function and may have the disease but have not been diagnosed. The primary risk factor for COPD is smoking. Additional risk factors include exposure to second-hand smoke, occupational dusts and chemicals, air pollution, heredity, a history of childhood respiratory infections, and socioeconomic status. COPD has a major negative impact on quality of life including imposing limitations on the ability to work, normal physical exertion, household chores, social and family activities, and sleeping patterns. In addition to these problems with daily life, there is obviously much suffering associated with emergency department visits and hospitalizations caused by COPD exacerbations.

The objective of this article is to summarize the economic and clinical burdens of COPD in the USA for the general clinician. Discussion of the burden of this disease refers to the impact of COPD measured by financial cost, morbidity, and mortality. Additionally, the natural history of COPD will be briefly reviewed as well as the cost of this disease and its treatment. Evidence-based diagnosis and management will be discussed including future directions for COPD therapy.

Natural history of COPD
COPD is usually a progressive disease. Chronic cough and sputum are most common in some patients, but dyspnea associated with effort is the predominate feature in others. Although certain patients have a slowly progressive reduction in pulmonary function, others experience a rapid decline. A small degree of reversible airway obstruction may be detected in some COPD patients, but in most the airway obstruction is close to irreversible. While there is no cure for COPD, progression of the disease may be slowed by smoking cessation and avoiding exposure to other noxious agents. Furthermore, optimal management is proven to reduce exacerbations and enhance quality of life.

The natural history and time course of the onset of COPD exacerbations is not fully understood. Exacerbations of COPD are defined as an acute event characterized by worsening respiratory symptoms, beyond normal day-to-day variations, which require a change in medication. In ambulatory patients with stable COPD, predictors for two or more exacerbations annually include older age, chronic mucus hypersecretion, and decreased forced expiratory volume in the first second of expiration (FEV₁). Aaron et al found that COPD exacerbations exhibit two distinct patterns: gradual and sudden onset. Exacerbations with sudden onset are associated with increased respiratory symptoms but reduced exacerbation recovery times. Hospitalization for COPD exacerbations increases the risk of subsequent mortality regardless of baseline pulmonary function. Patients with comorbidities such as diabetes and coronary artery disease are more likely to be hospitalized for exacerbations of COPD. COPD is rarely seen in isolation but rather is often managed with comorbidities including heart failure, lung cancer, diabetes, hypertension, and dyslipidemia. Systemic inflammation likely plays a key role in the development of these concomitant disease states, and elevated biomarkers such as C-reactive protein are associated with an increased risk of comorbidities.

End-stage COPD is characterized by progressively worsening dyspnea during activities of daily living, and finally even at rest. Additional symptoms, including cough, difficulty in expectoration, loss of energy, weakness, weight loss, and insomnia, are frequently seen. Understandably, these patients also suffer from anxiety, panic, and depression. Hospital admissions become more common, and patients spend the remaining months of their lives at home, or with hospice care, slowly losing their independence. Among end-stage COPD patients, factors such as current smoking, comorbidities, low body mass index, and hypoxemia are predictors of survival.

Cost of COPD treatment in the USA
Given the prevalence of COPD in the USA, it is imperative to understand the economic impact a disease of this significance can have. As can be imagined, this debilitating and chronic disease carries a significant and substantial economic burden on individuals and society. Unfortunately, this burden is only going to worsen. According to Murray and Lopez, the 30-year projections for COPD are staggering. Presently, COPD is already the third most common cause of death in the USA, and is expected to match this mark worldwide by the year 2020. Morbidity data follows this same trend. Multiple factors are responsible for this continued growth including continued tobacco use and dependence combined with the overall increase in life expectancy (allowing individuals to have a greater likelihood of exposure to COPD risk factors).

As with all chronic diseases, the associated economic burden is felt in the form of both direct and indirect costs. In 2010, the cost of COPD in the USA was projected to be approximately $49.9 billion, which includes $20 billion in indirect costs and $30 billion in direct health care expenditures. With a currently estimated prevalence of COPD reaching 12 million in the USA, a mean cost of
over $4000 per patient per year could be projected. These costs can be expected to continue to rise as more patients with evidence of lung function impairment are diagnosed through recent advances in COPD screening initiatives.

Indirect costs refer to the morbidity and mortality caused by the disease. These figures stem from the disabling effects of COPD, which are most commonly exhibited as days off from work.\(^2\)\(^1\) Physical exertion and sleeping patterns are effectively reduced in 70% and 50% of COPD patients, respectively. In addition, half of all COPD patients (51%) state that their disease hinders their ability to work.\(^2\) Thornton Snider et al\(^3\) conducted an economic evaluation of the association between the diagnosis of COPD in Americans more than 50 years old with employment status and the collection of disability benefits. These researchers found that when patients have COPD, there is a 9 percentage point reduction in the likelihood of being employed, along with a 4 percentage point increase in the probability of collecting Social Security Disability Insurance. These figures rival similar data for patients who have experienced a stroke and exceed all other estimates for major chronic health conditions in the USA including cancer, diabetes, heart disease, and hypertension.\(^3\) While the comparative indirect economic burden of COPD is noticeably substantial, indirect costs represent only the minority of total dollars spent on the care of COPD patients in the USA.

Direct health care costs, accounting for nearly two-thirds of total COPD dollars, are those related to the detection, treatment, prevention, and rehabilitation of a disease, which include: physician office visits, hospitalizations, home care, and medications.\(^4\) As would be expected, there is a direct relationship between the severity of COPD and the overall cost of care at the patient level.\(^2\)\(^1\) Data indicate that with each progressive stage of COPD, as defined in a previous GOLD guideline, patients with stage I COPD experienced the lowest direct cost of $1681 per patient per year, stage II patients $5037 per patient per year, and those in stage III had the highest cost of $10,812 per patient per year.\(^4\) Hospitalization was identified as the most important cost variable across all three stages of COPD. The hospital stay accounts for roughly 45%–50% of the total direct cost generated by COPD patients.\(^4\)\(^5\) Table 1 describes the median (due to non-normally distributed data) annual costs of COPD treatment.

<table>
<thead>
<tr>
<th>Cost categories</th>
<th>Severity of COPD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stage I(^*)</td>
</tr>
<tr>
<td>Total medication cost (%)</td>
<td>$512 (31)</td>
</tr>
<tr>
<td>Total non-medication costs (%)</td>
<td>$489 (29)</td>
</tr>
<tr>
<td>Hospitalization cost (%)</td>
<td>$680 (40)</td>
</tr>
<tr>
<td>Total cost</td>
<td>$1681</td>
</tr>
</tbody>
</table>

Notes: \(^*P\) \(< 0.01\) for each cost variable and total cost across the three severities of COPD. All figures are in US$ per patient.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Table 1 Annual median costs for COPD treatment based on disease severity

Unfortunately, with increasing age and disease severity, exacerbations only become more frequent and severe.\(^6\) These reports emphasize the need to further optimize COPD diagnosis and management. Reducing exacerbations will not only improve quality of life and slow the progression of disease, but also has the potential to significantly reduce direct health care expenditures.
How is your COPD? Take the COPD assessment test™ (CAT)

This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive Pulmonary Disease) is having on your well being and daily life. Your answers, and test score, can be used by you and your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.

For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response for each question.

Example:  
I am very happy [X]  
I am very sad

---

Total score

---

Figure 1: Evaluative questions from the COPD Assessment Test (CAT).

COPD Assessment Test and the CAT logo is a trade mark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline group of companies. All rights reserved.

Last Updated: February 24, 2012.

Abbreviation: COPD, chronic obstructive pulmonary disease.

Improving COPD diagnosis and management

Currently, patients are diagnosed with COPD following a multifactorial assessment that includes clinical presentation, symptomatology, and risk factors in combination with the gold-standard of spirometry. Hallmark symptoms of COPD include sputum production, cough, and progressive dyspnea. All patients with suspected COPD should undergo spirometry, which is a necessary component for diagnosis. A pertinent and thorough medical history and physical examination are
both essential elements for clinical assessment in a patient with suspected COPD. In addition, differential diagnosis should be assessed to ensure that an appropriate diagnosis is made.2,23

Misdiagnosis and under-diagnosis continues to be a focal problem in the management of COPD.24 While clinicians agree that spirometry is essential for COPD diagnosis, assessments are often omitted in the primary care setting due to various limiting factors.25 Barriers to appropriate spirometry evaluation include lack of time for assessment, lack of available resources, and inadequate training of personnel for accurate measurement. Sufficient training for primary care clinicians26 and enhanced population screening initiatives for high-risk patients24,27 may increase frequency, accuracy, and confidence in spirometry screening practices.

Despite streamlined, appropriate implementation of spirometry, differential diagnosis in COPD is challenging. In particular, differentiation between asthma and COPD can be difficult for clinicians due to substantial overlap in disease presentation and symptoms. A recent study indicates that a spirometry diagnosis of COPD could be made in approximately 17% of patients previously diagnosed with asthma alone.28 Furthermore, patients with COPD can exhibit some respiratory function reversibility, mimicking patients with an asthma diagnosis. Indeed the possibility of both disorders coexisting is likely more common than expected and can influence management strategies.27 Clinicians should place importance on a thorough medical history and utilize guidance from international guideline resources to ensure proper classification of these patients.2

Due to the aforementioned challenges of diagnosis, various analyses report diagnosis primarily in later stages of the disease. Patients who fall into these later stages of COPD before diagnosis classically exhibit less response to treatment modalities. In addition, while pulmonary function decline is slower in earlier stages of COPD, it becomes more rapid in more advanced disease.30 In short, advances resulting in earlier diagnosis can significantly influence the clinical course of COPD management and the natural history of disease progression.

As well as enhancing the frequency and efficiency of spirometry screening, population screening tools have emerged as options to facilitate earlier diagnosis of COPD. These tools attempt to simplify identification of COPD in the general population by providing a straightforward means for individuals to discuss their respiratory symptoms with a clinician. The self-scored COPD population screener questionnaire (COPD-PS) is one such tool that attempts to encompass a broad group of individuals for screening regardless of smoking history, previous diagnosis, or other clinical information.31 A score from questionnaires such as the COPD-PS is used by clinicians to determine whether or not supplementary assessment of potential COPD diagnosis is necessary. Because the positive predictive value of the COPD-PS is not sufficient for accurate diagnosis alone (approximately 57%), it is important to note that this tool is meant specifically for identification purposes rather than to be used as an exclusive diagnostic test.31 Although further validation and fine tuning of population screening questionnaires such as the COPD-PS are necessary, these tools will likely play a more substantial role in the early identification of COPD in the future.

A key future component of effective COPD disease management includes an appropriate assessment of disease severity through symptom evaluation to guide therapy. Although spirometry is essential for diagnosis, its role seems to be less well defined in regard to ongoing disease state management. While some sources still promote spirometry use in bronchodilator reversibility testing, this test is no longer recommended due to lack of efficacy as a tool to predict treatment response.2 Various assessment tools have been established to better assess COPD disease progress and severity.

The Modified British Medical Research Council (mMRC) questionnaire22 and the COPD Assessment Test (CAT) provide a standardized means of COPD-related health status assessment (Figure 1). These tools present a format for assessing the impact of COPD on quality of life indicators to help guide clinicians to properly select appropriate, guideline-recommended treatment strategies.2 While the mMRC only evaluates the impact of shortness of breath, the CAT includes assessments of COPD impact on activities of daily living. A recent randomized controlled study indicates that the CAT is a disease-specific instrument that significantly improves the assessment of COPD severity of illness.33 These assessment tests are now recommended as a standard means of assessment during patient follow-up visits2 and are used in combination with spirometry and assessment of exacerbation risk to guide therapy.

Pulmonary imaging has become an area of interest that may play a more significant role in COPD assessment and care in the future. Quantitative pulmonary imaging can provide greater insight into lung structure and function in comparison with spirometry which can only assess disease severity.31 Computed tomography (CT) can provide detailed images of lung structure while magnetic resonance imaging (MRI) can help assess lung function including lung
parenchyma function and airway thickening. Significant weaknesses of these imaging studies include the need for both CT and MRI studies for appropriate lung assessment, availability, and cost. Although CT is fast and provides high-resolution images, regular CT scans can promote harmful cumulative radiation. While these imaging modalities can help clinicians assess patients further, they carry with them both disadvantages and risks while their true role in COPD care remains to be established.

Smoking is the single most influential factor in the natural history of COPD. It must be the first step in modifying the clinical course of COPD and reducing the rate of decline in lung function. For this reason, a focus on smoking cessation interventions is likely the principal and most influential factor in COPD management. Although the most important strategy, smoking cessation may prove especially challenging in these patients, and should be approached utilizing both behavioral and pharmacological therapy when appropriate. Various first line pharmacotherapy options for tobacco dependence, are available, including varenicline, bupropion SR, and nicotine replacement therapies: treatment selection should be patient-specific, focusing on particular patient characteristics, preference, and contraindications. A comprehensive and multilevel approach to smoking cessation including both patient counseling and support along with pharmacotherapy is optimal, and this approach has been shown to provide the best benefit for long term quit rates.

Although controversial due to low quality evidence, long-term oxygen therapy has been shown to decrease mortality in patients with severe resting hypoxemia. Likewise, it is currently a common non-pharmacologic therapy recommendation in this patient population in the hope of also improving functional performance and health-related quality of life. However, the same benefit has not been found in patients with mild to moderate hypoxemia. Despite the need for additional studies to illustrate the benefits of long-term oxygen therapy, ethical constraints of withholding oxygen therapy will likely be a limiting factor in future prospective studies.

The anti-inflammatory and immunomodulatory effects of macrolide antibiotics as described in the literature, along with increased rates of early clinical response with their use, have increased their use in patients with acute infectious COPD exacerbations. These desirable effects have led to the investigation of macrolides for a potential role in the prevention of acute COPD exacerbations. Modest improvements in time to acute exacerbations, frequency of exacerbations, quality of life, and also number of moderate to severe exacerbations have all been reported with the use of macrolide prophylaxis in patients with COPD. As described previously, any reduction in acute exacerbations has the potential to translate into significant economic savings.

However, it is important to note that none of these studies have indicated a mortality benefit, and significant adverse effects and collateral damage from year-long use of macrolide therapy should be seriously considered. Recently, the US Food and Drug Administration issued a Drug Safety Communication on the widespread use of azithromycin, and the risk of potentially fatal heart arrhythmias. Ototoxicity and the potential for drug–drug interactions should also be considered with long-term macrolide therapy. Perhaps of even greater concern, the spread of antibiotic resistant isolates poses a threat to both macrolides and various other antimicrobials that exhibit similar mechanisms of action, and are thus affected by similar resistance gene mutations. For these reasons, antibiotic prophylaxis is not endorsed by current guidelines.

**Current and emerging options for treatment**

The primary goal of chronic COPD management is stabilization of chronic disease and prevention of exacerbations. Exacerbations not only incur significant morbidity and mortality, but also negatively impact the natural history of the disease causing a progression in disease severity. While current available pharmacologic therapy for COPD does not prevent progression of the disease, it does offer symptom relief and prevention of exacerbations. Treatment guidelines on selection and escalation of therapy are available. Some direction is given on the appropriate order of agent initiation, but much is left to clinical judgment.

Bronchodilators are the mainstay of COPD management. Initial treatment for patients with few symptoms and low exacerbation risk consists of a short-acting bronchodilator, either short-acting beta₂-agonist (SABA) or short-acting muscarinic antagonist (SAMA) used as needed for breathlessness. Other options include a combination of SABA and SAMA or a long-acting bronchodilator; however, data for the combination of short-acting agents are limited and evidence for long-acting agents is focused on patients with more severe disease.

Progression of symptoms, and possible decline in FEV₁, warrant the use of long-acting bronchodilators over short-acting agents. Selecting either a long-acting beta₂-agonist
(LABA) or long-acting muscarinic antagonist (LAMA) should be based on patient response, preference, and affordability as limited data exist defining the best initial treatment. Some evidence suggests benefit of selecting tiotropium as the initial agent over a LABA, but data are limited. A recent review found equivocal evidence when comparing tiotropium to LABAs for COPD outcomes including quality of life, exacerbations, and mortality. Consideration must also be given to dosing schedule and inhalation device when selecting therapy. Indacaterol is currently the only LABA available that is dosed once daily, compared with formoterol and salmeterol which are dosed twice daily. Patients with severe symptoms that persist despite treatment with a single long-acting bronchodilator can be considered for combination bronchodilator therapy. Studies evaluating the combination of tiotropium and LABAs have shown improvement in lung function and dyspnea compared with either agent alone. At present, no means are available to deliver these agents together in one device.

A number of fixed-dose combinations containing ultra-LABAs and LAMAs given once daily are in development for the treatment of COPD.

Indacaterol/glycopyrronium, vilanterol/umeclidinium, and olodaterol/tiotropium bromide are all in clinical trials under investigation for once daily dosing. These agents would offer an option to patients who need combination therapy to control their symptoms, without increasing the burden of additional devices and the need for more than once daily dosing. Unfortunately, diminishing the number of delivery devices does not necessarily correlate to diminishing price, and therefore may not be the ideal option for all patients. Current average monthly costs of common COPD medications can be found in Table 2. Theophylline may be considered as an option if inhaled bronchodilator therapy is unavailable or unaffordable, but it is less effective and less well tolerated than inhaled bronchodilators.

For patients with frequent exacerbations with or without consistent symptoms, inhaled corticosteroids should be considered. This treatment is in addition to a LABA or LAMA and may even consist of “triple therapy” with all three agents, in patients with more severe disease. Evidence supports the use of the combination LABA/ICS over LABA alone in patients with severe airflow limitation or frequent exacerbations. However, data comparing LABA/ICS to tiotropium are limited but both have been shown to reduce exacerbations individually. Medications shown to reduce exacerbations in COPD are described in Table 3. Current LABA/ICS combinations, including salmeterol/fluticasone, formoterol/mometasone, and formoterol/budesonide, require twice daily administration. In addition to other twice daily dosed formulations, combinations of ultra-LABAs and ICS such as indacaterol/mometasone and vilanterol/fluticasone, dosed once-daily are currently being investigated.

Frequent exacerbations of COPD and unrelenting symptoms despite LAMA or LABA/ICS therapy may require consideration for progression to either triple therapy with LAMA and LABA/ICS or addition of a phosphodiesterase-4 inhibitor. Improvement in lung function has consistently been reported with triple therapy compared with LAMA or LABA/ICS alone; however, data on reduction in exacerbations have varied. Roflumilast, a phosphodiesterase-4 inhibitor, may be added if the patient has symptoms of chronic bronchitis and frequent exacerbations despite bronchodilator therapy. Despite less clear data in patients on ICS, roflumilast has been shown to

---

**Table 2 Cost of common COPD medications**

<table>
<thead>
<tr>
<th>Medication</th>
<th>Usual dose</th>
<th>Average monthly cost in US$</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProAir® HFA MDI</td>
<td>2 inhalations (90 mcg) every 4 to 6 hours as needed</td>
<td>$42</td>
</tr>
<tr>
<td>Atrovent® HFA MDI</td>
<td>1 inhalation (17 mcg) every 6 hours</td>
<td>$150</td>
</tr>
<tr>
<td>Combivent® Respimat®</td>
<td>1 inhalation (20 mcg/100 mcg) four times daily</td>
<td>$275</td>
</tr>
<tr>
<td>Combivent® MDI</td>
<td>2 inhalations (36 mcg/90 mcg) four times daily</td>
<td>$250</td>
</tr>
<tr>
<td>Xopenex HFA MDI</td>
<td>1 inhalation (45 mcg) every 4 to 6 hours as needed</td>
<td>$54</td>
</tr>
<tr>
<td>Spiriva® Handihaler®</td>
<td>18 mcg once daily</td>
<td>$220</td>
</tr>
<tr>
<td>Tudorza™ Pressair™</td>
<td>400 mcg twice daily</td>
<td>$265</td>
</tr>
<tr>
<td>Arcapta™ Neohaler™</td>
<td>75 mcg once daily</td>
<td>$192</td>
</tr>
<tr>
<td>SerEVENT® Diskus®</td>
<td>50 mcg twice daily</td>
<td>$166</td>
</tr>
<tr>
<td>Foradil® Aerolizer®</td>
<td>12 mcg twice daily</td>
<td>$160</td>
</tr>
<tr>
<td>Advair Diskus® (fluticasone propionate/salmeterol)</td>
<td>250/50 mcg twice daily</td>
<td>$225</td>
</tr>
<tr>
<td>Symbicort® (budesonide/formoterol fumarate)</td>
<td>160/4.5 mcg twice daily</td>
<td>$215</td>
</tr>
<tr>
<td>Daliresp® (roflumilast)</td>
<td>500 mcg daily</td>
<td>$210</td>
</tr>
</tbody>
</table>

**Abbreviations:** COPD, chronic obstructive pulmonary disease; HFA, hydrofluoroalkane; mcg, microgram; MDI, metered-dose inhaler.
be effective in reducing exacerbations in patients treated with long-acting bronchodilators. 73, 74

In addition to a variety of novel ultra-LABAs, LAMAs and combination bronchodilator and ICS therapies, other bronchodilators with a variety of mechanisms are also being considered for expanding therapeutic options for the treatment of COPD. Prostaglandin E receptor 4 (EP4), bitter taste receptors (TAS2Rs) of the tongue, and inhaled dual phosphodiesterase-3/phosphodiesterase-4 inhibitors are being evaluated as drug targets for COPD. 75 In addition, agents targeting CD8+ T cells, and inhibitors of NF-κB, chemokine-receptors 2 and 3, T-helper-17 cells and MAP kinase p38 are also being investigated for their role in managing chronic COPD. 76 Finally, the role of vitamin D supplementation on the disease course is also being evaluated in randomized trials. With over 50 new medications in the pipeline for the treatment of COPD, optimal management will continue to evolve and grow more complex with

Table 3 Reduction in COPD exacerbations 54–57, 59–61, 63–65

<table>
<thead>
<tr>
<th>Trial/duration</th>
<th>Intervention</th>
<th>Population</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calverley et al 12 months</td>
<td>Salmeterol + fluticasone Salmeterol Fluticasone Placebo</td>
<td>Moderate to severe COPD</td>
<td>↓ number of exacerbations for all active treatments compared to placebo (P = 0.003 for salmeterol and fluticasone alone, ( P &lt; 0.0001 ) for combo) ↓ number of exacerbations requiring oral corticosteroids for all active treatments compared to placebo (( P &lt; 0.0001 ) for combo and fluticasone, ( P = 0.003 ) for salmeterol and fluticasone alone) ↑ time to first exacerbation in budesonide/formoterol compared to all other groups (( P &lt; 0.05 )) ↓ total number of exacerbations in budesonide/formoterol compared to placebo (( P = 0.029 )) and budesonide alone (( P &lt; 0.05 )) but not budesonide alone (( P = 0.308 )) ↓ exacerbations requiring oral corticosteroids in budesonide/formoterol compared to placebo (( P &lt; 0.001 )) and budesonide and formoterol alone (( P &lt; 0.01 ))</td>
</tr>
<tr>
<td>Calverley et al 12 months</td>
<td>Budesonide + formoterol Budesonide Formoterol Placebo</td>
<td>Severe to very severe COPD</td>
<td>↓ in severe exacerbations with budesonide/formoterol compared to placebo (( P = 0.035 )) and formoterol alone (( P = 0.043 )) but not budesonide alone (( P = 0.385 )) ↓ in mild exacerbations in all treatments compared to placebo (( P &lt; 0.001 )) and budesonide/formoterol compared to budesonide (( P = 0.022 )) and formoterol (( P = 0.403 )) ↓ number of exacerbations for all active treatments compared to placebo (( P &lt; 0.001 )) and for combo compared to salmeterol (( P = 0.002 )) and fluticasone (( P = 0.02 )) ↓ number of exacerbations requiring systemic corticosteroids for all active treatments compared to placebo (( P &lt; 0.001 )) and for combo compared to salmeterol (( P &lt; 0.001 )) and fluticasone (( P = 0.02 )) ↓ number of exacerbations requiring hospitalization for salmeterol (( P = 0.02 )) and combo (( P = 0.03 ))</td>
</tr>
<tr>
<td>Szafranski W et al 12 months</td>
<td>Budesonide + formoterol Budesonide Formoterol Placebo</td>
<td>Moderate to severe COPD</td>
<td>↓ in moderate to severe exacerbations compared to placebo (( P = 0.029 )) and budesonide alone (( P = 0.308 )) ↓ number of exacerbations requiring oral corticosteroids in budesonide/formoterol compared to placebo (( P = 0.001 )) and budesonide and formoterol alone (( P &lt; 0.01 )) ↑ time to first exacerbation (( P = 0.028 )) and first hospitalization (( P = 0.055 )) ↓ frequency of exacerbations (( P = 0.031 )), exacerbation days (( P = 0.041 )), antibiotic days for exacerbation (( P = 0.015 )), unscheduled visits for exacerbations (( P = 0.019 )), and hospitalizations for exacerbations (( P = 0.047 ))</td>
</tr>
<tr>
<td>Calverley et al 3 years</td>
<td>Salmeterol + fluticasone Salmeterol Fluticasone Placebo</td>
<td>Moderate to severe COPD</td>
<td>↓ number of exacerbations for all active treatments compared to placebo (( P &lt; 0.001 )) and for combo compared to salmeterol (( P = 0.002 )) and fluticasone (( P = 0.02 )) ↓ number of exacerbations requiring systemic corticosteroids for all active treatments compared to placebo (( P &lt; 0.001 )) and for combo compared to salmeterol (( P &lt; 0.001 )) and fluticasone (( P = 0.02 )) ↓ number of exacerbations requiring hospitalization for salmeterol (( P = 0.02 )) and combo (( P = 0.03 ))</td>
</tr>
<tr>
<td>Wedzicha JA et al 2 years</td>
<td>Salmeterol + fluticasone Tiotropium</td>
<td>Severe to very severe COPD</td>
<td>No difference in overall exacerbation rates (( P = 0.656 )) or exacerbations requiring hospitalization (( P = 0.085 )) ↓ exacerbations requiring oral corticosteroids with salmeterol/fluticasone (( P = 0.039 )) ↓ exacerbations requiring antibiotics with tiotropium (( P = 0.028 ))</td>
</tr>
<tr>
<td>Niewoehner et al 6 months</td>
<td>Tiotropium Placebo</td>
<td>Moderate to severe COPD</td>
<td>↑ time to first exacerbation (( P = 0.028 )) and first hospitalization (( P = 0.055 )) ↓ frequency of exacerbations (( P = 0.031 )), exacerbation days (( P = 0.019 )), antibiotic days for exacerbation (( P = 0.015 )), unscheduled visits for exacerbations (( P = 0.019 )), and hospitalizations for exacerbations (( P = 0.047 ))</td>
</tr>
<tr>
<td>Tashkin DP et al 4 years</td>
<td>Tiotropium Placebo</td>
<td>Moderate to very severe COPD</td>
<td>↑ time to first exacerbation (( P &lt; 0.001 )) ↓ number of exacerbations (( P &lt; 0.001 )) ↓ number of moderate or severe exacerbations (( P = 0.003 ))</td>
</tr>
<tr>
<td>Calverley et al 52 weeks</td>
<td>Roflumilast Placebo</td>
<td>Severe to very severe COPD</td>
<td>↑ time to first exacerbation (( P = 0.0185 )) and second exacerbation (( P = 0.0014 ))</td>
</tr>
</tbody>
</table>

Abbreviation: COPD, chronic obstructive pulmonary disease.
balancing benefits of therapy with the limitations and needs of each patient.

In addition to pharmacologic therapies, a few non-pharmacologic therapies may also be considered for the treatment of COPD. Pulmonary rehabilitation is recommended to reduce dyspnea, improve health-related quality of life, and reduce hospital days and other measures of health-care utilization. Current guidelines recommend a program of at least 6 weeks duration that includes exercise training, smoking cessation, nutrition counseling, and education. Pulmonary rehabilitation has been recognized as cost-effective in the treatment of COPD, irrespective of its undetermined effect on mortality. Patients who experience shortness of breath when walking at their own pace on level ground should be offered pulmonary rehabilitation.

Various surgical interventions are available for consideration in the management of medically refractory, advanced stage COPD. Lung volume reduction surgery involves an excision of emphysematous lung tissue to decrease lung volume and reduce hyperinflation. Bullectomy can be considered for excision when air-filled pockets (bullae) are present in the lung affecting surrounding lung tissue. Lung transplantation is an additional alternative surgical option which can completely replace malfunctioning lung, but typically a waiting period is required, it is a more invasive surgical procedure, and transplantation carries serious risks such as organ rejection and the need for lifelong immunosuppressive therapy. Careful patient assessment and selection should include a comprehensive risk benefit assessment before consideration of surgical palliation.

Conclusion and future directions
COPD is a complex, multifactorial, and progressive disease associated with significant morbidity and mortality in the USA. The rising economic burden of COPD correlates with increases in disease severity, and hospital admissions and readmissions account for a significant bulk of cost across all stages of COPD. Early, appropriate behavioral and pharmacotherapy options to reduce COPD exacerbations are essential for slowing disease progression, increasing patient quality of life, and subsequently reducing the overall cost burden of this disease state.

Despite the known clinical and economic devastation this disease causes, a great deal remains unknown about optimal therapy. Specifically, more conclusive evidence is needed concerning ideal therapy selection and appropriate sequencing of therapy. Additionally, the role of screening tools in facilitating early diagnosis of COPD and the impact of early treatment on cost and patient outcomes need further delineation. Fortunately, a renewed interest in identifying new drug targets and novel pharmacotherapy for the management of COPD is being observed. It is imperative that the role these new agents play in the management of this disease is clearly elucidated. The anticipated high cost of these new therapies will ultimately have to be balanced with their overall benefit in disease state management and the specific medical and financial needs of the individual patient.

Disclosure
Dr Chris Finch is a speaker for GSK (Advair) and consultant for Sunovion Pharmaceuticals (Brovana). No financial support was received for this manuscript. The authors report no conflicts of interest in this work.

References